Approaches to the Development and Quality Control of Vaccine for Allergen-Specific Immunotherapy of Ragweed Pollen Allergy

Abstract

Ragweed (Ambrosia artemisiifolia) pollen allergy is a major and growing public health problem worldwide, with clinical manifestations ranging from rhinitis and conjunctivitis to asthmatic episodes and anaphylaxis. The major ragweed allergen, Amb a 1, exhibits high IgE-binding potential and triggers type 1 hypersensitivity reactions. Although allergen-specific immunotherapy (AIT) effectively induces long-term immune tolerance, conventional extract-based formulations face critical limitations including batch-to-batch variability, heterogeneous allergen composition, IgE-mediated adverse reactions, inconsistent immunogenicity, and poor patient compliance. This critical review synthesizes and evaluates published evidence on current synthetic vaccine strategies for ragweed AIT, with emphasis on their design, immunological performance, and quality control considerations. This review critically evaluates current approaches to synthetic vaccine development for ragweed AIT, with a particular focus on peptide-based constructs, recombinant proteins, DNA vaccines, and adjuvant-enhanced formulations, alongside corresponding quality control strategies. The available evidence indicates that synthetic vaccines provide a more rational, molecularly characterized trajectory for producing optimized AIT products with improved safety profiles, enhanced clinical efficacy, reduced injection frequency, and improved batch standardization relative to extract-based immunotherapy. These advances highlight the potential of synthetic vaccine platforms to support personalized immunotherapy and more effective disease-modifying treatment of allergic disorders.

1. Introduction

Ragweed (Ambrosia artemisiifolia, family Asteraceae) is distributed across multiple continents and produces pollen capable of triggering IgE-mediated allergic reactions ranging from allergic rhinitis and conjunctivitis to severe asthmatic episodes, bronchospasm, and anaphylaxis, with serious consequences for human health [1]. Cross-reactive sensitization further complicates clinical management. Globally, approximately 30% of the population suffers from allergic conditions [2], and allergy incidence in Russia is estimated at up to 21% [3]. Despite decades of pharmacological research, existing symptomatic therapies do not modify the underlying immunological course. In ragweed pollen allergy, accurate characterization of the molecular composition of allergenic source should be considered during immunotherapy development because clinically relevant allergens, including Amb a 1 and Amb a 11, and their associated isoforms, contribute to the antigenic composition that must be controlled in vaccine formulation and standardization.

Allergen-specific immunotherapy (AIT) is the only disease-modifying treatment for allergic disorders, including ragweed pollen allergy. AIT promotes multiple immunomodulatory effects: it stimulates allergen-specific IgG antibodies, represses Th2 cells, activates regulatory T (Treg) cells, and blocks IgE-mediated mast cell activation. Collectively, these mechanisms induce long-term immune tolerance [4,5]. Passive immunization with recombinant monoclonal allergen-specific IgG antibodies significantly reduces allergic reactions in sensitized patients during allergen exposure, confirming the central role of IgG in AIT success [6]. In the case of ragweed AIT, this provides an important basis for the formulation of vaccines that could induce protective allergen-specific IgG responses with minimal reactivity mediated by allergen-specific IgE.

Nonetheless, conventional extract-based AIT faces persistent limitations. Heterogeneity in the allergen content between batches, variability in allergen composition, and the presence of non-allergenic components contribute to inconsistent immunogenicity and safety concerns [7,8]. Such limitations are particularly relevant to ragweed pollen vaccines, where variations in the representation and quantity of clinically important allergen molecules may affect the preparation, potency, consistency, and immunogenic activity of the final product. Thus, allergen selection and characterization of allergenic molecular forms are significant steps in vaccine development and quality control.

Standard subcutaneous immunotherapy (SCIT) requires an initial build-up phase consisting of weekly injections for 3–6 months, followed by maintenance dosing at 3–6-week intervals for a minimum of three years, with therapeutic effects persisting for approximately 2–3 years after treatment discontinuation [9,10]. These treatment demands impose substantial compliance burdens on patients. Consequently, the development of novel vaccine approaches with consistent composition, enhanced IgG induction, reduced injection frequency, and improved IgE-blocking efficacy is therefore a clinical priority. In this context, recombinant allergens, allergen-derived peptides, and other molecularly defined vaccine constructs offer strategies for incorporating selected ragweed allergen components into more controlled and reproducible formulations.

In spite of these challenges, existing evidence indicates that the establishment and standardization of molecularly defined and synthetic vaccine systems may lead to more predictable and controlled enhancement in the safety, efficacy, and reproducibility of AIT for ragweed-associated allergic disease. Nevertheless, the successful development of such systems requires not only appropriate molecular design and selection of relevant ragweed allergen components, but also analytical methods capable of verifying their identity, purity, quantity, consistency, structural integrity and potency throughout production.

Therefore, this critical review explores the current approaches to the development and quality control of vaccines for AIT of ragweed pollen allergy, with particular emphasis on rational vaccine design, standardization, and translational considerations aimed at improving immunogenicity, reducing allergenicity, and ensuring consistent quality control. The review integrates existing knowledge about novel synthetic vaccine platforms and production techniques to pinpoint design features and quality control elements that are essential to address the challenges encountered with conventional extract-based immunotherapies. Special attention is directed toward how molecularly defined ragweed allergens, recombinant constructs, and peptide-based approaches may counteract the compositional limitations of conventional ragweed extracts, and how their corresponding quality attributes can be controlled during vaccine development.

As displayed in Figure 1, the left side illustrates the immune reaction that occurs upon exposure to ragweed pollen allergen (Amb a1) in the absence of AIT. Initial contact with the respiratory mucosal epithelium triggers cytokines release, which activates dendritic cells and induces Th2 cell differentiation. This response triggers B cells to mediate an allergic response by producing allergen-specific IgE antibodies that bind to FcεRI receptors on mast cells. Upon repeated exposure to the allergen, cross-linking of IgE on mast cells results in degranulation and the release of inflammatory mediators, including histamine, prostaglandin D2 (PGD2), and leukotrienes (LTs). As a result, symptoms like sneezing, itching, rhinorrhoea, edema, bronchospasm, and mucous inflammation develop.

Figure 1. Comparative scheme of the immune response to ragweed pollen: without AIT and with AIT.

The immunological changes involved in AIT are shown on the right side of the figure. Multiple allergen exposures at controlled microdoses induce immune tolerance and the recruitment of Treg and T-helper 1 (Th1) cells. These responses inhibit the Th2-mediated activity, promote the generation of allergen-specific IgG4 and IgG1 antibody levels, and decrease the levels of allergen-specific IgE. There is an increase in blocking antibodies, which prevent mast cell and basophil degranulation by blocking the interaction of allergen with IgE. Consequently, allergic inflammation is decreased and clinical symptoms are progressively alleviated.

2. Methodology

2.1. Review Design

This study adopted a critical narrative review methodology to evaluate current approaches to the development and quality control of vaccines for AIT of ragweed pollen allergy. While systematic reviews aim to synthesize predefined evidence quantitatively, critical narrative reviews aim to synthesize and criticize heterogenous evidence in order to offer conceptually oriented understanding, to evaluate methodological advances, identify current gaps, and suggest future research directions. This review, therefore, integrates evidence from the fields of immunology, molecular vaccine technology, pharmaceutical quality control, pharmacokinetics, regulatory science and pharmacoeconomics to deliver a comprehensive overview of how to rationally develop next-generation AIT vaccines.

2.2. Literature Search Strategy

Given the multitude of new research around molecular allergen vaccines and the diversity of newly emerging synthetic vaccine platforms, a structured literature search was conducted to identify existing evidence relevant to the development and quality control of molecular allergen vaccines for ragweed pollen allergy. The aim of the review was to critically assess the published literature on vaccine design strategies, immunologic mechanisms, manufacturing methods and approaches to analytical characterization, quality control, pharmacokinetic (PK) properties, and regulatory and pharmacoeconomic implications of emerging synthetic AIT platforms.

Peer-reviewed articles from the PubMed, Scopus, Web of Science, and Google Scholar electronic databases were searched up to June 2026. Where appropriate, relevant regulatory guidance documents and technical reports published by the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA), the World Health Organization (WHO) and other regulatory authorities were also consulted in support of the scientific literature. Selected publications were included in reference lists and manually screened for further relevance to the initial database search.

The search strategy incorporated combinations of Medical Subject Headings (MeSH) and free-text keywords, including ragweed allergy, Ambrosia artemisiifolia, allergen-specific immunotherapy, AIT, subcutaneous immunotherapy, SCIT, sublingual immunotherapy, SLIT, synthetic allergen vaccine, recombinant allergen, peptide vaccine, DNA vaccine, nanoparticle vaccine, virus-like particle, quality control, quality assurance, standardization, analytical characterization, pharmacokinetics, and pharmacoeconomics. The search strategy was developed to capture both established and emerging approaches to the rational design, development, and quality assessment of synthetic allergen vaccines.

2.3. Eligibility Criteria

The review prioritized studies investigating ragweed pollen–specific allergen immunotherapy and the development of ragweed-based vaccines. Scientific relevance to allergen-specific immunotherapy and contribution to understanding of development, characterization, quality control, and clinical translation of synthetic allergen vaccines guided the selection of studies. Eligible publications were those that discussed the development of recombinant allergens, peptide-based vaccines, DNA vaccines, nanoparticle and virus-like particle delivery systems, molecular allergen engineering, and analytical characterization, pharmacokinetics, quality control, regulatory evaluation, and pharmacoeconomics of recombinant and peptide vaccines. Studies that were not related to allergen-specific immunotherapy and vaccine development, editorials, duplicate publications, and conference abstracts with insufficient methodological detail were excluded.

Due to the relative scarcity of studies specifically investigating synthetic vaccines against ragweed pollen allergy, the review also included well-established studies involving other clinically relevant pollen allergens like birch (Bet v 1) and grass pollen allergens, which provided transferable mechanistic, immunological, manufacturing, or analytical insights relevant to the development of ragweed vaccines. Such non-ragweed studies were included only where the principles underlying its development or quality control were considered transferable to ragweed vaccine development. This strategy allowed for more comprehensive analysis of modern vaccine design concepts while maintaining the primary focus on ragweed allergen immunotherapy.

2.4. Evidence Extraction and Synthesis

Information regarding vaccine platform, allergen composition, molecular design strategy, manufacturing/purification process, adjuvants, immune mechanisms, efficacy outcome, safety, analytical characterization techniques, quality control parameters, pharmacokinetic parameters, regulatory requirements, and pharmacoeconomic considerations were extracted from selected literature. Focus was dedicated to molecularly defined vaccine constructs to optimize allergenicity, immunogenicity, manufacturing consistency and clinical translation.

Available evidence was critically synthesized using a thematic narrative approach, given the considerable heterogeneity across vaccine platforms, experimental models, analytical methods and reported outcome measures, and quantitative synthesis. Findings were comparatively analyzed with respect to key themes of vaccine development strategies, molecular design principles, analytical characterization, quality control methodologies, pharmacokinetics behavior, regulatory expectations and pharmacoeconomic considerations. This methodological approach enabled the identification of current advances, existing limitations and the future directions of research, while ensuring that the available evidence was assessed based on its scientific value and relevance for the next generation of safe, highly standardized, and clinically effective allergen-specific immunotherapy vaccines for ragweed pollen allergy.

3. General Approaches to AIT Vaccine Development

Advances in allergen vaccine development have been driven by efforts to reduce IgE-mediated adverse effects while enhancing immunogenic responses [11]. Notable strategies include peptide-based vaccines, recombinant allergen vaccines, DNA vaccines, and virus-like particle (VLP) or nanoparticle delivery systems. These approaches collectively represent a paradigm shift from crude extract preparations towards rationally designed, molecularly characterized vaccine compositions [12]. For ragweed pollen allergy, these approaches are particularly relevant as they support the controlled selection, production, engineering, and delivery of defined allergen components, while providing more precise control over vaccine composition and associated quality attributes. Where evidence specific to ragweed is unavailable or inadequate, findings from other clinically relevant pollen allergens are considered for their transferable principles to vaccine design, manufacturing, and quality-control processes.

3.1. Recombinant Allergen-Based Vaccines

Recombinant vaccines are generated through laboratory-based engineering using defined allergen molecules, offering consistent standardization and high purity in contrast to natural allergen extracts subject to inter-batch variation. For ragweed vaccine development, this approach allows selected clinically relevant allergen molecules to be produced as defined components rather than relying exclusively on the heterogeneous composition of natural pollen extract.

Following the identification of Amb a 1, polyA+ mRNA is isolated and used as a template for cDNA synthesis, which is cloned into an expression vector and introduced into a host organism (e.g., Escherichia coli) for recombinant allergen production. Ragweed-specific studies have reported the molecular cloning of Amb a 1 cDNA and subsequent expression and purification of recombinant Amb a 1-related proteins in E. coli for immunological characterization [13,14]. This recombinant approach has also been explored using other clinically relevant pollen allergens. For example, a recombinant vaccine based on short peptides from IgE-binding regions of Bet v 1 fused to the PreS domain of the hepatitis B surface protein triggered protective IgG and IgA antibodies against birch pollen and cross-reactive food allergens [15]. Although this strategy was demonstrated using a non-ragweed pollen allergen, it can be adapted to the molecular design of ragweed allergen constructs that are intended to have reduced IgE reactivity and induced protective IgG responses. A similar approach using a hybrid protein containing epitopes from Bet v 1 and related food allergens eliminated IgE-mediated reactivity while maintaining T-cell activation and inducing protective cross-reactive IgG antibodies [16]. However, single recombinant allergens may not adequately capture all IgE responses in polysensitized patients [17], necessitating exploration of complementary strategies.

3.2. Peptide-Based Vaccines

Peptide-based vaccines employ defined amino acid sequences derived from major allergens to stimulate the desired immune responses while minimizing adverse reactions. Rational design involves epitope mapping through immunoinformatics and experimental validation, with T-cell epitopes computationally predicted using MHC binding affinity, antigenicity, and population coverage algorithms [18,19]. Peptide chains are assembled stepwise by Fmoc-mediated solid-phase synthesis, followed by reverse-phase HPLC purification to pharmaceutical-grade purity exceeding 95% [20,21]. In the context of ragweed pollen allergy, peptide-based approaches provide the possibility of selecting defined regions from clinically relevant ragweed allergens for incorporation into vaccine constructs, instead of administering the complete heterogeneous allergen extract. This makes allergen selection and peptide identity important development parameters, with peptide sequence, purity, quantity, potency, and stability serving as essential quality control measures. This targeted approach allows peptide vaccines to deliver precise immunogenic sequences that stimulate selective T-cell activation, unlike crude extracts containing multiple proteins and contaminants [22]. Short synthetic peptides can also produce IgG4 blocking antibodies with minimal IgE cross-linking and induce T-cell changes associated with long-term remission in allergic airway disease [23]. However, the low intrinsic immunogenicity of isolated peptides consistently necessitates adjuvants or advanced delivery modalities to optimize therapeutic outcomes [24].

3.3. DNA Vaccines

DNA vaccines administer sequences encoding an antigen of interest, typically a hypoallergen, to promote cell-mediated immunity that counterbalances Th2 dominance, reducing the risk of anaphylactic shock with fewer doses than with traditional immunotherapy. In vaccine formulation for ragweed, this offers an alternative to administering whole natural allergen extracts or purified allergen proteins, as selected ragweed allergen components are incorporated into a well-defined genetic construct. Plasmid DNA constructs employ strong mammalian promoters such as the cytomegalovirus (CMV) immediate-early promoter for high-level transcription [25]. Tools such as NeuralCodOpt automate codon optimization, significantly increasing translational efficiency The potential of DNA-based approaches for ragweed allergy is supported by evidence showing that a DNA vaccine combined with purified Amb a 1 amplified protective Th1 immune responses in nasal tissue while inhibiting allergic Th2 responses. The antigen also promoted IFN-γ-skewed antibody class switching toward IgG and downregulated Th2-mediated IgE responses [26]. Although conceptually distinct from conventional plasmid DNA vaccination, it indicates that DNA-based technologies can modulate immune responses to Amb a 1. Consequently, quality assessment emphasizes confirmation of the DNA construct’s molecular identity, sequence, purity, integrity, and stability over direct characterization of the expressed allergen protein. Despite potent efficacy in pre-clinical animal models, DNA vaccines face limitations in human applications due to suboptimal immunogenicity and transfection efficiency [27], requiring further development to overcome delivery barriers.

3.4. Virus-like Particles (VLP) and Nanoparticle Delivery Systems

Nanoparticles serve as carriers and adjuvants in allergen immunotherapy, offering antigen stability, targeted delivery, and co-delivery capabilities, resulting in improved therapeutic activity and tolerability [28,29]. The rise in nanoparticle-based allergen delivery has catalyzed heightened interest in molecularly characterized allergen vaccines [30]. For ragweed vaccine development, VLPs and nanoparticles provide adaptable delivery platforms for molecularly defined ragweed allergens, allergen-derived peptides, and related constructs in a manner that allows antigen presentation and delivery to be optimized independently of conventional crude pollen extracts.

CpG-adjuvanted PLGA nanoparticles have been shown to induce IgG2a antibody synthesis and suppress allergenic airway inflammation in murine models [31]. However, concerns remain regarding the toxicological profiles and biodistribution of nanoparticles, and their safety must be thoroughly assessed prior to clinical translation [32]. Moreover, the incorporation of ragweed allergens to VLP or nanoparticle delivery vehicles necessitates the evaluation of other product attributes that must be characterized such as allergen identity and content, particle attributes, allergen loading, purity, stability and batch consistency. Together, these novel approaches support recombinant allergen vaccines as prominent candidates capable of superseding crude extracts with controllable antigenic compositions and regulated immune responses [33].

Figure 2 presents a proposed workflow for developing a recombinant vaccine candidate specific to the major ragweed pollen allergens Amb a 1 and Amb a 11.

Figure 2. Workflow for the development of a recombinant vaccine targeting the major ragweed pollen allergens Amb a 1 and Amb a 11. The workflow was developed based on established principles of molecular allergen characterization, recombinant allergen production, and peptide-based allergen vaccine development [33,34,35].

The development process begins with the identification and characterization of the major ragweed pollen allergens, Amb a 1 and Amb a 11. Following allergens identification, B cell IgE epitopes are screened and identified for their immunological relevance and inducing allergic responses. The selected epitopes are subsequently utilized for the generation of candidate peptides, which include peptide design, synthesis, purification and preliminary testing. The peptides generated are then added to recombinant-based constructs to form the vaccine candidate. Vaccine formulation is followed by quality control to ensure purity, stability, and consistency of the recombinant constructs. Finally, the vaccine candidate undergoes pre-clinical trials to evaluate its potential efficacy, immunogenicity and safety before further clinical development.

4. Detailed Approaches in Ragweed Pollen Allergy Vaccine Development

Genetically engineered ragweed allergens selectively incorporate major allergens such as Amb a 1 and Amb a 11, minimizing co-purified non-relevant constituents associated with inconsistent potency and unwanted immune responses [36]. Various recombinant vaccine strategies have been developed to maximize safety and efficacy, including recombinant wild-type allergens, hypoallergenic derivatives, allergen-derived fusion proteins, and adjuvanted formulations.

4.1. Recombinant Wild-Type Allergens

Recombinant wild-type allergens provide regulated and repeatable antigen generation, avoiding the heterogeneity of natural pollen extracts, and ensuring batch-to-batch consistency crucial for diagnostics and immunotherapy This approach is supported by findings that insect cell-expressed Amb a 1.01 exhibits allergenic properties similar to its natural counterpart, supporting its application in molecular allergy diagnostics and immunotherapy [36]. Sensitization to Amb a 11 has also be linked with respiratory symptoms and asthma pathology, further supporting its clinical significance [1]. However, the persistent expression of IgE epitopes limits the biomedical safety of wild-type recombinant allergens, necessitating refinement into safer hypoallergenic derivatives.

4.2. Hypoallergenic Ragweed Derivatives

Hypoallergenic derivatives minimize allergic sequelae while maintaining immune recognition by modifying IgE-binding domains through site-directed mutagenesis, peptide cleavage, or chemical derivatization, reducing systemic reactions while retaining T-cell immunogenicity [37]. Modified Amb a 1 constructs have shown improved results, though maintaining adequate immune activation while lowering IgE-mediated allergenicity remains a challenge [38]. However, reducing IgE recognition may also reduce immunogenicity, highlighting the inherent challenge of balancing the safety–efficacy ratio in vaccine design [39].

An alternative strategy involves systematic in silico screening of B-cell IgE epitopes. Using three-dimensional protein modeling and multiple epitope prediction algorithms, nine B-cell IgE epitopes in Amb a 1 and seven in Amb a 11 were identified as potential targets for inclusion in recombinant vaccine constructs [40]. By targeting validated epitope sequences rather than whole allergen proteins, this strategy enables rational design of hypoallergenic derivatives that retain T-cell recognition while attenuating IgE-binding activity, thereby mitigating the safety–efficacy trade-off associated with large-scale protein modifications.

4.3. Fusion Proteins and Carrier-Bound Ragweed Constructs

Fusion of ragweed allergens to carriers such as VLPs or bacterial proteins enhances immunogenicity, improves immunostimulation, and reduces IgE-mediated hypersensitivity risks [41]. Although the clinical data supporting carrier-bound ragweed constructs remains limited, established findings do not contradict the design principles that have been demonstrated in molecularly defined carrier-bound vaccine constructs of other pollen allergens.

Evidence from other pollen allergens supports the potential of this approach. In a multicenter, double-blind, placebo-controlled trial involving 181 participants, BM32, a recombinant grass pollen vaccine containing non-allergenic peptides from four major grass pollen allergens fused to the hepatitis B virus preS carrier protein, was well tolerated and produced substantial clinical improvement with allergen-specific IgG blocking antibodies and modulation of allergic inflammation, validating the safety and immunogenic potential of recombinant B-cell epitope-based vaccines [42]. Similar results have been reported for ragweed, where an Amb a 1 recombinant fusion molecule reduced IgE allergenicity while increasing IgG responses [43]. Despite these advances, clinical translation is hindered by challenges in molecular vaccine design and manufacturing that is reproducible, as well as regulatory demands for product characterization, standardization, and clinical development [33,44].

4.4. Adjuvant-Enhanced Ragweed Vacciine Formulations

Adjuvanted recombinant vaccines employ immunomodulators such as CpG oligodeoxynucleotides (ODNs) or monophosphoryl lipid A (MPLA) to shift immune responses toward Th1 or Treg pathways, overcoming allergic inflammation. CpG-adjuvanted PLGA nanoparticles induced IgG2a antibody synthesis and suppressed allergenic airway responses in murine models [31]. Adjuvants can strengthen or alter allergen-specific immune responses, although their clinical performance differs depending on the formulation. Despite this potential, CpG-ODN-based approaches for ragweed allergy have not achieved significant efficacy in clinical studies [45]. Variability in patient responses and ongoing safety concerns related to adjuvant constituents remain limitations requiring further study for widespread clinical application.

5. Pharmacokinetics of AIT Vaccines

5.1. General Considerations

Pharmacokinetics (PK) describes how administered substances are processed over time [46]. Unlike conventional pharmacological agents where PK centers on plasma drug concentration, allergen vaccine pharmacokinetics must consider both the allergen molecule and the immunological persistence it induces [47]. These considerations are especially important for the development of ragweed vaccines, as variations in allergen structure, molecular size, formulation, and delivery system could affect the distribution, longevity, and immune exposure of the vaccine’s antigen. The ultimate aim is to maximize dosing schedules to sustain immune responses rather than merely maintaining therapeutic serum concentrations. Therapeutic effects of allergen vaccines arise from progressive immune system restructuring, including induction of allergen-specific IgG antibodies (especially IgG4), regulatory T cells (Tregs), and suppression of type 2 immune responses [48]. The PK assessment for AIT must therefore incorporate conventional absorption, distribution, metabolism, and elimination (ADME) parameters alongside immunopharmacodynamic measures such as allergen-specific IgG production, antigen presentation dynamics, T-cell priming in draining lymph nodes, and T-cell blockade duration.

5.2. Routes of Administration and Absorption

Route of administration largely dictates absorption and the scale of immune responses. In SCIT, allergen is deposited in subcutaneous tissue where it interacts with immune cells and the extracellular scaffold [49]. Aluminum-based adjuvants (alum) bind allergen to their surface, though recent findings indicate that most allergen does not remain bound to the alum after a few hours [50]. Depot effect activity is significantly mediated by improved allergen localization and enhanced uptake by antigen-presenting cells (APCs), rather than by sustained slow allergen dissolution [51]. In SLIT, allergens are absorbed across the highly vascularized oral epithelium, primarily through mucosal dendritic cells including Langerhans cells, which can capture the antigen within minutes [52]. SLIT requires substantially greater doses than SCIT due to reduced bioavailability from salivary proteolytic degradation [53]. For synthetic ragweed peptides, smaller peptides diffuse and absorb more rapidly than full-length Amb a 1 protein, and molecular alterations reducing IgE reactivity can modify absorption kinetics.

5.3. Distribution and Elimination

Following administration, allergens reach draining lymph nodes via passive diffusion through lymphatic capillaries or via active transport by dendritic cells, which migrate from the injection site to T-cell zones where naive T cells detect antigen-loaded APCs and trigger adaptive immune responses [54]. Allergen-adjuvant complexes are avidly ingested by tissue-resident macrophages and inflammatory monocytes, which migrate to draining lymph nodes via CCR7/CCL21 chemotactic cues to initiate T-cell responses [55]. Molecular weight and structural configuration of synthetic and natural allergen formulations significantly affect distribution patterns. Natural Amb a 1 (approximately 38 kDa) is transported to lymph nodes through lymphatics, whereas shorter synthetic peptides (2–10 kDa) diffuse more rapidly [56].

Clearance of allergenic proteins is governed by proteolytic degradation, renal ultrafiltration of proteins below approximately 70 kDa, and mucociliary clearance [57,58,59]. Native allergen extracts are cleared within hours to days, whereas depot formulations may persist for weeks [60]. Biopersistence of aluminum adjuvant particles, which are carried by immune cells over time with small amounts accumulating in organs, raises long-term safety considerations [61]. Modifications such as D-amino acid substitution reduce protease recognition and enhance breakdown resistance. PEGylation sterically prevents protease access and raises hydrodynamic radius to reduce renal clearance rates [60].

5.4. Regulatory Aspects

The European Medicines Agency (EMA) 2008 Guideline on Allergen Products emphasizes that conventional ADME-based pharmacokinetic studies are not suitable for allergen preparations due to their complex protein mixtures and predominantly local immunological mechanisms of action. For synthetic peptide-based vaccine products, characterization generally includes quality attributes such as sequence identity, purity, aggregation, and physicochemical stability [62,63]. These analytical principles can provide a framework for evaluating molecularly defined peptide-based ragweed vaccine candidates. The EMA Guideline on the Clinical Development of Products for Specific Immunotherapy also highlights the importance of appropriate dose-finding during clinical development, particularly for purified allergens, such as native, recombinant, and synthetic peptide preparations for which the rationale for allergen selection and study-population should be clearly justified [64,65].

6. Approaches to Quality Control of Allergen Vaccines

6.1. General Principles

Quality control in allergen vaccines encompasses standard processes to verify identity, quantity, and impurity profiles, thereby ensuring safety, efficacy, and batch-to-batch consistency throughout production and clinical use. Allergen extracts from unmodified pollen require strict quality control due to biological variability across seasons, geographic regions, and collection processes, which substantially impacts the concentration and potency of principal allergenic proteins [66]. This variability is specifically important for ragweed pollen extracts where the presence or absence of clinically relevant allergens (Amb a 1, Amb a 11 and their related molecular forms) and the amounts of these allergens in the final allergen preparation may account for variations in the composition and potency of the extract. Regulatory authorities including the FDA and EMA have established detailed specifications and guidelines for physicochemical evaluation of allergens, requiring compliance with approved analytical procedures to validate identity, purity, safety, and potency [67]. The presence of multiple protein isoforms in natural allergen extracts significantly complicates the quality control process, requiring high-resolution analytical techniques for precise identification and quantification [68]. For ragweed vaccine development, these challenges underscore the importance of identifying and quantifying clinically relevant allergen components and establishing suitable specifications for their identity, content, purity, potency, and inter-batch consistency. Conversely, synthetic allergen vaccines provide pure, reproducible, and predictable composition, offering improved standardization and elimination of batch variability [69].

6.2. Molecular Identity Characterization

For synthetic ragweed vaccines, trypsinolysis of the protein followed by liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis establishes amino acid sequences, post-translational modifications, and sequence variations [70]. Nuclear magnetic resonance (NMR) spectroscopy verifies the three-dimensional structure and dynamics of synthetic allergen constructs, though its application is constrained by instrument complexity and experiment duration [71]. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) determines molecular weight, purity, and disulphide bond patterns, while HPLC or UPLC with appropriate detection provides high confidence in target allergen content. Although the characterization of protein aggregation by SDS-PAGE alone is inherently limited, complementary techniques, particularly size-exclusion chromatography (SEC), can therefore be employed to identify and quantify soluble protein aggregates [72]. These characterization approaches are particularly important for recombinant Amb a 1 variants, which have shown more than a 100-fold decrease in IgE-dependent mediator-release activity compared with the natural allergen. Recombinant Amb a 1α also retained major T-cell reactivity while showing lower IgE binding, supporting its potential as a hypoallergenic immunotherapeutic candidate [73].

6.3. Modern Quality Control Strategies

Beyond molecular identity, contemporary quality control of synthetic allergen vaccines adopts a holistic, multi-attribute approach integrating physicochemical methods with functional immunological assays [74]. Regulatory agencies (FDA, EMA) increasingly require monitoring of product-specific critical quality attributes (CQAs), including purity, folding stability, aggregation, and IgE-binding consistency [75]. Advanced platforms such as multi-attribute monitoring (MAM) mass spectrometry are now replacing traditional batch-release tests, ensuring rigorous safety, potency, and batch-to-batch consistency for clinical translation [76,77].

7. Comparative Overview of Quality Control Paradigms

The transition from natural crude extracts to molecularly defined vaccine formulations has introduced new quality control demands. For ragweed pollen allergy, the substantial seasonal and geographic variability of crude extracts and the presence of multiple clinically relevant allergens (Amb a 1, Amb a 11, and related components) complicate classical standardization. Table 1 presents a comparative overview of quality control paradigms for classic versus next-generation ragweed allergen immunotherapy vaccines.

Table 1. Comparative overview of quality control paradigms: classic vs. next-generation ragweed allergen immunotherapy vaccines.

Quality Control Attribute	Classic AIT (Natural Allergen Extracts)	Improved AIT (Synthetic, Recombinant, Nanoparticle)
Source Material & Starting Material	High variability; dependent on biological source (pollen), season, geographical region, and extraction processes. Raw materials undergo stringent production control such as pollen purity, but variability between batches remains a significant challenge [66,68].	Defined and consistent; designed based on chemically synthesized peptides, recombinantly expressed proteins, or formulated nanoparticles. Starting materials such as, synthetic reagents and allergen-encoding nucleic acids, are well-characterized, ensuring batch-to-batch consistency [69].
Composition & Identity	Complex, heterogeneous mixtures containing multiple allergenic and non-allergenic proteins, isoforms, and other biological molecules. Identity is typically confirmed using qualitative protein profiling techniques such as SDS-PAGE and immunoblotting, alongside IgE-binding assays; however, the complexity of allergen extracts and cross-reactivity frequently limit precise molecular identification [78].	Simple, well-defined, and homogeneous composition. Identity is confirmed using advanced analytical techniques such as liquid chromatography tandem mass spectrometry (LC-MS/MS) for peptide sequence and post-translational modifications [70,79].
Potency	Traditionally based on biological potency of allergen extracts, including its reliance on functional assays (IgE binding, mediator release, and limitations such as variability, and presence of non-allergenic components.	Based on defined physicochemical composition such as protein concentration and immunological assays. Potency is linked to specific functional attributes, such as reduced IgE binding (hypoallergenicity) and preserved T-cell reactivity measured using targeted assays like ELISA inhibition or basophil activation tests [73].
Purity & Impurity control	Natural extracts include both allergenic and non-allergenic components, contributing to variability and complexity. There is absence of defined “target molecule” for purity; instead, consistency of the complex mixture is assessed [68].	Purity criteria for the active pharmaceutical ingredient are strictly defined. Example: For recombinant proteins, stringent detection and limits on host cell proteins (HCPs), residual DNA, and endotoxins [80,81]. For synthetic peptides, purity defined by HPLC and confirmed by mass spectrometry [82]. For nanoparticles, additional physicochemical characterization includes particle size, polydisperity, and particle concentration.
Stability Monitoring	Monitoring changes in complex protein profile and biological potency over time helps to predict stability. Complexity of mixtures further complicates tracking degradation pathways [83,84].	High-resolution, analyte-specific methods are employed to monitor stability. In synthetic vaccines, this involves tracking the structural integrity of the intended molecular entity, such as by RP-HPLC and MS, and its associated functional properties, which allows precise detection of degradation processes and supports ambient storage with suitable formulation [70].
Regulatory Framework & Standardization	Regulatory frameworks issued by agencies such as the FDA and EMA highlight the need for consistency in the manufacturing processes and a stable final product profile [85].	Critical quality attributes (CQAs) such as identity, purity, and potency are established and monitored through validated analytical methods, which confer regulatory flexibility alongside enhanced predictability of the final product [86].

Table 1 shows a comparative overview of quality control paradigms in classical and next-generation ragweed allergen immunotherapy (AIT) vaccines. A comparison of the important quality control characteristics of traditional allergen-based natural ragweed extract products to new vaccine formulations of synthetic peptides, recombinant proteins and nanoparticle-based products. The source materials for the classical AIT products are of biological origin with complex allergen composition, leading to natural variability in identity, potency, purity and stability evaluations. Consequently, quality control measures are mainly concerned with batch uniformity and biological activity of the batches despite the variations in raw materials and extract composition.

In contrast, next-generation ragweed AIT vaccines are developed from well-defined and highly characterized starting materials, allowing greater control over product composition and manufacturing processes. The use of advanced analytical technologies allows us to assess identity, potency, purity and stability with great precision and to set clearly defined quality attributes. Collectively, the recombinant, synthetic, and nanoparticle-based system support increased batch uniformity, minimizes impurity variability, and results in more robust stability profiling relative to conventional extracts. The progression to molecularly defined vaccine constructs illustrates a shift from process-dependent quality assurance to product-driven quality control, thereby enhancing reproducibility, regulatory compliance, and predictability in clinical efficacy.

8. Vaccine Structure Classes and Corresponding Quality Control Strategies

Analytical methods are chosen to measure identity, potency, purity, quantity, and stability, and to control process-related impurities. The molecular structure and production process of each vaccine class determine applicable quality control approaches. For molecularly defined ragweed vaccine candidates, these platform-specific methods provide a framework for confirming the identity and integrity of selected ragweed allergen components, controlling product- and process-related impurities, and appropriate antigen content, stability, and batch-to-batch consistency. Table 1, Table 2, Table 3, Table 4 and Table 5 summarize analytical methods for the principal synthetic vaccine structure classes, with emphasis on their application to synthetic allergen vaccines.

Table 2. Analytical methods for peptide-based allergen vaccines (quality, quantity, impurities).

Aspect	What is Assessed	Main/Typical Methods	Description/Specifications for Quality Control Parameters
Identity & sequence	Correct amino-acid sequence and composition	LC–MS/MS, amino acid analysis, MALDI-TOF MS [87]	Establishes that the synthetic peptides are consistent with the designed sequence and expected molecular weight.
Purity and the presence of impurities	Truncated peptides, deletion sequence, aggregation	RP-HPLC or UPLC, SEC-HPLC, analytical TLC (early stage) [87]	≥95% regulatory limits quantify purity for clinical application
Quantity (peptide content)	Peptide concentration per vial	Amino acid analysis, UV/Vis- spectrophotometry [87], reversed-phase HPLC	Determines peptide quantity in the final formulation to eliminate batch variation and maintain dose accuracy.
Stability	Degradation, oxidation	Stability studies monitored by RP-HPLC/UPLC, LC–MS [87]	Purity and integrity of vaccines are monitored during shelf life and storage conditions

Table 2 highlights the principal analytical techniques used in the quality control of peptide-based allergen vaccines, addressing identity, purity, potency (content), and stability. Quality control begins with confirmation of peptide identity and amino acid sequence using advanced analytical techniques such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), amino acid analysis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The methods ensure the synthesized peptides have the intended structure and properties.

Table 3. Analytical methods for DNA allergen vaccines.

Aspect	What is Assessed	Main/Typical Methods	Description/Specifications for Quality Control Parameters
Plasmid identity & structure	topology (supercoiled)	agarose gel electrophoresis, restriction digestion patterns and capillary gel electrophoresis [88]	Confirms that the intended allergen gene is transfected into the plasmid to, and then plasmid remains in supercoiled form
Purity & impurities	Host-cell DNA/RNA, proteins, endotoxin, residual antibiotics	Anion-exchange HPLC for plasmid vs. genomic DNA, residual DNA, endotoxin test, residual antibiotic assays [89]	Discarding contaminants from host cells to preserve safety range
Quantity (DNA content)	Plasmid DNA concentration and dose	UV spectrophotometry (A260), qPCR [89]	Determines DNA content and supports accurate dosing per shot
Stability	Plasmid integrity during storage	Stability over long duration monitored by HPLC [89]	DNA integrity preserved under favorable storage condition such as standard temperature, defined formulations, etc.

Table 3 explains the analytical methods used for the quality control of DNA-based allergen vaccines. The following table lists the main analytical techniques used to assess identity, purity, amount, and stability of DNA-based allergen vaccines. The first step in quality control is to verify plasmid identity and structural integrity through agarose gel electrophoresis, restriction digestion analysis and capillary gel electrophoresis. The methods demonstrate successful incorporation of the desired gene encoding the allergen of interest and confirm that the plasmid is in an active supercoiled form that is essential for biological activity.

Table 4. Analytical methods for recombinant allergen-based vaccines.

Aspect	What is Assessed	Main/Typical Methods	Description/Specifications for Quality Control Parameters
Identity & structure	Correct amino acid, molecular mass, folding	1H-nuclear magnetic resonance (1H-NMR), circular dichroism (CD) spectroscopy, dynamic light scattering (DLS), SDS-PAGE, immunoblotting (IB), enzyme-linked immunosorbent assay (ELISA), and MR-assay (mediator release assay) of RBL (humanized rat basophil leukemia cells) [90]	Confirms correct molecular weight and antigen specificity
Purity & process-related impurities	Host-cell protein (HCP) assays	affinity chromatography [91], ELISA [91,92], Size-exclusion chromatography (SEC-HPLC) Reversed-phase and ion-exchange HPLC [93], Residual DNA assays, endotoxin test	Purity profiling of main allergen following separation from aggregates.
Quantity (antigen content).	Active pharmaceutical ingredient concentration per dose	antigen-specific ELISA [91], Reversed-phase HPLC [93],	Measures and control the dose of active pharmaceutical ingredient in final products
Stability	Structural and functional changes in storage process	Stability studies monitored by HPLC, MS, ELISA and immunoassays [93,94]	Structural integrity and potency are strongly linked to longer shelf life and storage

Table 4 summarizes the analytical methods employed for the quality control of recombinant allergen-based vaccines. The main analytical methods used for evaluating identity, purity, quantity and stability of recombinant allergen-containing vaccines are summarized. Protein identity and integrity are verified by a range of physicochemical, immunological, and functional assays as part of the quality control program. The correct amino acid sequence, molecular weight, conformational structure and antigenic properties of the recombinant allergen are confirmed by techniques including proton nuclear magnetic resonance (¹H-NMR), circular dichroism (CD) spectroscopy, dynamic light scattering (DLS), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), immunoblotting, enzyme-linked immunosorbent assay (ELISA) and mediator release assays.

Table 5. Analytical methods for nanoparticle-mediated allergen vaccines.

Aspect	What is Assessed	Main Methods Commonly Used	Description/Specifications for Quality Control Parameters
Identity & higher-order structure	Structural integrity of allergen which follows nanoparticle association, size of nanoparticles	SDS-PAGE, LC–MS, circular dichroism spectroscopy, Western blot [95,96], dynamic light scattering (DLS)	The nanoparticle remains neutral with no interactions with the allergen that could cause degradation
Purity & process-related impurities	Allergen purity, aggregates, host-cell proteins/DNA, plus nanoparticle impurities (free NPs, unreacted linker, degradation products)	Chromatographic methods (SEC-HPLC, RP-HPLC) [95], Inductively coupled plasma mass spectrometry (ICP=MS) for free NPs/metal impurities [97]	Removal of potential impurities to ensure safety
Quantity (antigen content)	Total protein and specific allergen loading on nanoparticles per dose	RP-HPLC—bound allergen vs. free allergen after NP dissociation, ELISA [77,95]	Allergen and NP dose in rational quantity for optimal reproducible immune response
Stability	Nanoparticle size, antigen release, structural integrity during storage	SEC-HPLC/RP-HPLC for aggregates/release; MS/CD for PTMs/folding, DLS/NTA for particle size, ELISA/BAT for IgE binding, basophil activation retention [77,95,96].

Table 5 shows the analytical methods used for quality control of nanoparticle-mediated allergen vaccines. The table above summarizes the principal analytical methods employed for the assessment of identity, purity, quantity, and stability of nanoparticle-mediated allergen vaccines. Quality control begins with the evaluation of allergen identity and higher-order structure following nanoparticle association. Structural integrity, molecular characteristics, nanoparticle size distribution are confirmed by analytical techniques including sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), liquid chromatography–mass spectrometry (LC-MS), circular dichroism (CD) spectroscopy, Western blotting and dynamic light scattering (DLS). These techniques prevent any alteration or degradation of the allergen structure that might change its immunological properties when incorporated into nanoparticles.

Purity assessment focuses on identifying peptide-related impurities like truncations, deletion variants and aggregates. Several chromatographic methods are widely used to assess purity, including reversed-phase high-performance liquid chromatography (RP-HPLC), ultra-performance liquid chromatography (UPLC) and size-exclusion chromatography (SEC-HPLC), with all of these used to determine conformance to regulatory requirements. Furthermore, amino acid analysis, UV–visible spectrophotometry and chromatographic methods are used to quantify peptides, thereby reducing batch-to-batch variation and assuring correct dosage.

Stability evaluation includes the evaluation of potential pathways of degradation such as oxidation and structural changes during storage and shelf-life studies. RP-HPLC, UPLC and LC-MS are high-resolution analytical techniques that enable identification of changes in peptide integrity and help ensure product quality over time. Overall, these analytical tools offer a comprehensive solution for ensuring identity, purity, consistency in potency and long-term stability of the allergen vaccines based on peptides.

Assessment of purity focuses on the detection and quantification of the host cell DNA, RNA, protein content, endotoxins and residual antibiotics. The techniques used for analysis include anion-exchange high-performance liquid chromatography (HPLC), endotoxin testing and residual contaminant assays to ensure levels of impurities are within safe limits. Plasmid DNA concentration is also measured using UV spectrophotometry and quantitative PCR (qPCR) to ensure accurate dose determination and reduce batch-to-batch variability.

Stability studies are conducted to test for plasmid integrity and stability during storage and handling procedures. Monitoring is typically done by chromatographic and molecular analytical techniques to identify structural degradation or conformational modifications which could influence vaccine performance. Overall, these analytical approaches represent a powerful tool to assure quality, safety, uniformity and long-term stability of DNA-based allergen vaccines prior to clinical application.

Impurities that can be present during the manufacture of recombinant proteins are detected and quantified in the process of purity assessment. These include, for example, the host cell proteins, residual DNA, endotoxins, protein aggregates, and contaminants associated with the manufacturing process. Purity profiles are assessed using a number of analytical methods including affinity chromatography, ELISA, size-exclusion high-performance liquid chromatography (SEC-HPLC), reversed-phase HPLC and ion-exchange HPLC to ensure the target allergen is effectively separated from impurities and degradation products. These enable production of highly purified and consistent vaccine preparations.

The concentration of the active pharmaceutical ingredient flowing in the final process formulation is determined by quantitative analysis. Allergen content and dosage can be measured using antigen-specific ELISA and chromatographic methods. Structural and functional changes that could happen during storage and handling are further evaluated in stability studies. Monitoring is typically carried out by HPLC, mass spectrometry, ELISA and other immunologic assays to monitor the integrity and biological activity of the protein over time. Conclusively, these analytical methods offer a comprehensive quality control system to guarantee identity, purity, efficacy, and stability of recombinant allergen-based vaccines for clinical use.

The assessment of purity is based on the identification and exclusion of product- and process-related impurities such as protein aggregates, host cell proteins, remaining DNA, free nanoparticles, unreacted linkers or degradation products. Chromatographic methods like size-exclusion high-performance liquid chromatography (SEC-HPLC) and reversed-phase high-performance liquid chromatography (RP-HPLC), and elemental analysis techniques like inductively coupled plasma mass spectrometry (ICP-MS) are used to determine purity profiles and to verify effective contaminant removal. As a result, the analyses are helpful to ensuring product safety and consistency in the manufacture.

Allergen loading and nanoparticle concentration in the final formulation is performed through quantitative analysis. To separate bound and unbound allergen fractions, and to assure correct dosage, methods such as RP-HPLC and allergen-specific enzyme-linked immunosorbent assays (ELISA) are used. Stability studies assess size changes, antigen release and structural changes in the nanoparticles during storage. Generally, the monitoring is done by chromatographic, spectroscopic, immunological and particle-sizing methods to evaluate the aggregation, conformational stability, allergenicity and biological activity of the product over time. In summary, these analytical strategies offer a comprehensive quality control system for the identity, purity, consistency and long-term stability of nanoparticle allergen vaccines intended for clinical use.

9. Pharmacoeconomics of AIT

According to the World Health Organization, allergic diseases rank fourth among leading chronic diseases worldwide. More than 300 million people suffer from asthma and approximately 500 million from allergic rhinitis, with 15–20% of atopic patients experiencing severe clinical manifestations [98]. In the United States, 27.2% of children aged 0–17 years suffer from one or more allergy types, while the figure stands at 31.8% among adults [99,100]. Within the context of ragweed pollen allergy, pharmacoeconomic considerations are pertinent to vaccine development because the long duration of conventional AIT may generate significant treatment burden, whereas next-generation vaccine strategies are designed to minimize the number of doses and improve treatment practicality.

The traditional method of AIT delivery is subcutaneous injection (SCIT) under physician supervision. Since the 1990s, sublingual administration in the form of drops and tablets (SLIT) has provided a patient-administered alternative, with the first sublingual allergen product (Staloral, Stallergenes) appearing on the global pharmaceutical market. Introduction of rapidly dissolving sublingual tablets from ALK-Abello A/S in early 2020 gave new impetus to widespread AIT use, including a sublingual ragweed pollen therapeutic allergen relevant for southern European and Russian regions [101,102].

According to the Russian analytical company RNC Pharma, the retail market for AIT medications totaled 35.9 million dollars in 2025, with 257,300 packages sold representing a 6.5% decrease compared to 2024. Demand increases during winter months due to pre-seasonal initiation requirements, with average retail prices ranging from 103 to 154 dollars per standard package [103]. This market context is pertinent to the introduction of new ragweed AIT vaccines and suggests that economic and practical factors, including cost, treatment duration, and injection frequency are relevant considerations in addition to immunological performance and product quality.

In the Russian Federation, 65 trade names of allergen extract-based preparations are officially registered, of which 34 are used therapeutically in AIT (see Table 6). Only six (9.2%) are imported products, with all others produced domestically by NPO Mikrogen. The standard regimen for the registered ragweed pollen allergen product requires 32 injections administered over more than 30 days, illustrating the considerable compliance burden of conventional AIT [104]. Consequently, the development of molecularly defined ragweed vaccines requiring fewer administrations could potentially reduce treatment-related resource use and patient burden; however, their economic advantage would need to be demonstrated through direct pharmacoeconomic evaluation rather than inferred from dosing frequency alone.

Table 6. Quantitative characteristics of preparations based on allergen extracts registered in the Russian Federation.

ATC Code	Therapeutic Chemical Group of Preparations Based on Allergen Extracts	Number of Trade Names, Units
		Diagnostic	Therapeutic (AIT)
V01AA01	Bird feather allergens	-	-
V01AA02	Grass pollen allergens	22	22
V01AA03	Household allergens (house dust mite)	6	4
V01AA04	Fungal and yeast allergens	-	-
V01AA05	Tree pollen allergens	8	8
V01AA07	Insect allergens	-	-
V01AA08	Food allergens	19	-
V01AA09	Fabric allergens	-	-
V01AA10	Flower allergens	-	-
V01AA11	Animal allergens	7	-
V01AA20	Other allergens (bacterial)	3	-
Total		65	34

Table 6 quantitative characteristics of preparations based on allergen extracts registered in the Russian Federation. The table shows the distribution of allergen extract-based preparations registered in the Russian Federation according to the Anatomical Therapeutic Chemical (ATC) classification system. The registered products are categorized based on the allergen source and intended application such as diagnostic preparations and therapeutic formulations for allergen immunotherapy (AIT). Grass pollen allergens make up the largest category with 22 registered diagnostic and 22 therapeutic preparations, followed by food allergens, tree pollen allergens, animal allergens, and household allergens, which are mainly house dust mites.

An example is Allergard, a recombinant vaccine developed for birch pollen allergy. Unlike conventional AIT, Allergard, developed by the Institute of Immunology, Federal Medical and Biological Agency of Russia, contains hypoallergenic fragments rather than the whole allergen, stimulating protective IgG antibodies while blocking IgE production. Clinical trials initiated in October 2024 entered Phase III in February 2026, with initial results showing significantly reduced symptoms in most patients and complete symptom absence in 25%, with a favorable safety profile following five subcutaneous administrations [105]. Although Allergard was developed to treat birch pollen allergy, the reduced dosage regimen offers a useful comparator for considering how molecularly defined allergen vaccines may influence treatment burden and future pharmacoeconomic evaluation of similar ragweed vaccine strategies.

Analysis of the consumption changes and average retail prices of AIT medications on the Russian pharmaceutical market from 2024 to 2025 shows that the sales of AIT medications were highest in the winter months, with 39.5 thousand packages sold in January 2024 and a peak of 41.8 thousand in January 2025. Thereafter, the consumption trend waned slightly, reaching its lowest in June 2025 (8.0 thousand packages) and September 2025 (10.0 thousand packages). Towards the end of 2025, there was a rebound in demand, which reached 37.9 thousand packages in December.

In contrast, average retail prices, however, had smaller fluctuations during the same time interval. As of September 2025, the prices of constellations were ranging from 112 to 154 dollars per package, and the highest price was recorded in January 2024 (122 dollars). Despite the reduction in consumption observed during several periods of the study, retail prices remained relatively stable. In general, the seasonal pattern reflects the pre-seasonal initiation requirements of AIT, with demand increasing during winter months when patients seek treatment for the upcoming allergy season.

The allergen extracts and pollen predominate among the therapeutic preparations being proposed for use in AIT, which corresponds with their confirmed use in the management of respiratory allergic diseases. Several allergen groups such as food, animal, bacterial, and other environmental allergens are mainly or exclusively represented by diagnostic products. Furthermore, certain allergen groups, such as those of birds’ feathers, fungal and yeast, insects, fabric and flowers, had no registered diagnostic or therapeutic preparations.

Overall, the registration profile demonstrates a greater emphasis on allergen extracts typically associated with allergic rhinitis and respiratory hypersensitivity, specifically grass pollen, tree pollen, house dust mite and others, representing the majority of the therapeutic products approved for allergen immunotherapy in the Russian Federation.

Therefore, pharmacoeconomic evaluations of future molecularly defined ragweed vaccines should extend beyond acquisition costs to include treatment duration, cumulative administration frequency, healthcare resource use, patient adherence, and reduction in the burden of conventional extract-based AIT.

10. Conclusions

The development of molecularly defined vaccines for ragweed pollen allergen immunotherapy represents an innovative approach to combat the global burden of allergic disease. This strategy directly addresses the key limitations of traditional extract-based AIT, including batch variability, inconsistent potency, and safety concerns. Natural allergen extracts suffer from inherent heterogeneity, uneven allergen content, variable immunogenicity, and dosage inconsistencies, rendering uncertain clinical efficacy and raising the risk of IgE-mediated adverse events. In contrast, molecularly defined vaccine platforms, such as recombinant allergens, synthetic peptides, DNA vaccines, and nanoparticle-based delivery systems, offer a potential for antigen engineering, better immunologic targeting, safety, and manufacturing consistency. Further development of these platforms for ragweed pollen allergy depends on the rational selection and detailed characterization of clinically important ragweed allergens, particularly Amb a 1, Amb a 11, and their relevant molecular forms, to establish formulations that deliver adequate immunological coverage with reproducible manufacturing and robust quality control.

Beyond advances in vaccine design, this review identifies the need to thoroughly characterize and control these next-generation allergen vaccines, as well as provide a careful and standardized regulatory review during their development. New analytical methods provide detailed information on molecular identity, purity, potency, stability and impurities from the manufacturing process, which will facilitate reproducible manufacturing and enhanced batch-to-batch consistency. Similarly, exploring the pharmacokinetic profile, regulatory considerations, and pharmacoeconomic factors helps to frame the clinical potential and future implementation of new allergen-based platforms.

Altogether, the available evidence points to a paradigm change from biologically derived allergen extracts to molecularly characterized vaccine systems. Preserving rational antigen design, further advances in analytical technologies, standardized manufacturing processes, and evidence-based regulatory pathways will be key to the design of vaccines that are safe, effective, and clinically reproducible for long-term disease treatment and better outcomes for patients with ragweed pollen allergy.